Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SX 682

Drug Profile

SX 682

Alternative Names: SX-682

Latest Information Update: 07 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syntrix Biosystems
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Malignant melanoma

Most Recent Events

  • 01 May 2019 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03161431)
  • 01 May 2019 Phase-I/II clinical trials in Malignant melanoma (Late-stage disease, Inoperable/Unresectable, Monotherapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03161431)
  • 07 Feb 2019 SX 682 is available for licensing as of 07 Feb 2019 (Syntrix Biosystems pipeline, February 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top